.Nature Medicine, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research study, after a typical consequence of 11 months, clients along with metastatic gastrointestinal growths that obtained biomarker-matched therapies based on flowing lump DNA profiling showed a greater clinical benefit than those obtaining unrivaled treatment.